By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

QuatRx Pharmaceuticals 

777 East Eisenhower Parkway
Suite 100
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-913-9900 Fax: 734-913-0743


SEARCH JOBS








Company News
Shionogi & Co., Ltd. Enters Into Exclusive License Agreement With QuatRx Pharmaceuticals To Market Ospemifene 3/2/2010 9:46:15 AM
QuatRx Pharmaceuticals Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) 9/10/2009 8:14:54 AM
QuatRx Pharmaceuticals Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy 7/29/2009 8:46:26 AM
QuatRx Pharmaceuticals Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3/31/2009 8:24:05 AM
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy 9/24/2008 8:59:43 AM
QuatRx Pharmaceuticals Initiates Second Phase 3 Study of Ophena(TM) in Women With Postmenopausal Vaginal Syndrome 9/4/2008 8:56:19 AM
QuatRx Pharmaceuticals Presents Results From Ophena(TM) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy 6/16/2008 7:50:29 AM
QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 1/4/2008 8:05:07 AM
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) 1/3/2008 7:50:12 AM
QuatRx Pharmaceuticals Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome 8/22/2007 8:57:17 AM
123
//-->